KPRX
KIORA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$2.76
+3.37%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.66
From 52W high−3.50%
Volume49290.00
Market cap$12.21M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$2.66
From 52W high
−3.50%
Volume
49290.00
Market cap
$12.21M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
P/E (TTM)
—
RSI (14)
54.1
MomentumView details →
1D Return
+3.37%
YTD Return
+34.01%
SummaryUpdated Jun 1, 2026
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) is a clinical-stage specialty pharmaceutical company founded in 1998 and headquartered in Salt Lake City, Utah. Originally incorporated as Eyegate Pharmaceuticals, the company rebranded to Kiora Pharmaceuticals in November 2021. The company went public in February 2015 and focuses exclusively on developing innovative therapies for ophthalmic diseases. As a clinical-stage biotechnology firm, Kiora currently generates minimal revenue while investing heavily in research and development of three primary drug candidates targeting various eye conditions.
Similar companies
Latest newsMore news →
Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 1, 2026.12d agoKiora Pharmaceuticals granted Chong Kun Dang Pharmaceutical Corporation an exclusive, sublicensable license to develop, manufacture, and commercialize its KIO-301 product for ophthalmology indications in South Korea, in exchange for a $1.0 million upfront fee, milestone payments, and double-digit royalties.33d ago